Targeting NAD biosynthesis in Mycobacterium tuberculosis

靶向结核分枝杆菌的 NAD 生物合成

基本信息

批准号：
8873087
负责人：
Konstantin V Korotkov
金额：
$ 7.52万
依托单位：
UNIVERSITY OF KENTUCKY
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-05-01 至 2017-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8873087
关键词：
Address Adverse effects Anabolism Animal Model Anti-Bacterial Agents Antibiotics Antitubercular Agents Bacillus anthracis Bacillus subtilis Biochemical Pathway Biological Assay Cell Death Cell physiology Communicable Diseases Complex Data Databases Development Drug Targeting Drug resistance in tuberculosis Effectiveness Enzyme Inhibitor Drugs Enzyme Inhibitors Enzymes Escherichia coli Extreme drug resistant tuberculosis Fingerprint Genus Mycobacterium Goals Growth Homologous Gene Human In Vitro Inhibitory Concentration 50 Intervention Lead Ligands Metabolic Pathway Methodology Methods Molecular Weight Multi-Drug Resistance Mycobacterium smegmatis Mycobacterium tuberculosis Nicotinamide adenine dinucleotide Nicotinamide-Nucleotide Adenylyltransferase Nicotinate-nucleotide adenylyltransferase Pathway interactions Pharmaceutical Preparations Pharmacologic Substance Property Public Health Publishing Recycling Reporting Research Roentgen Rays Role Staging Structure Testing Time Tuberculosis antimicrobial base chemotherapy combat design drug development drug discovery improved in vivo inhibitor/antagonist innovation insight mycobacterial next generation nicotinate mononucleotide nicotinic acid adenine dinucleotide novel pathogen programs public health relevance research study resistant strain scaffold screening small molecule small molecule libraries structural biology success treatment duration treatment strategy tuberculosis treatment virtual

项目摘要

DESCRIPTION (provided by applicant): Emergence of multidrug-resistant and extensively drug-resistant strains of Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), represents a major threat to TB control. There is an urgent need for development of new and more effective anti-tubercular drugs targeting previously unexplored cellular processes. The goal of this proposal is to find a novel class of antimicrobial compounds active against Mtb. Nicotinamide mononucleotide adenylyltransferase (NadD), an essential enzyme of NAD biosynthesis, represents a highly promising target for drug development against bacterial pathogens. In recent years there have been a number of NadD inhibitors developed and validated against Escherichia coli, Bacillus subtilis and B. anthracis. Published data indicate tha NadD is required for the growth and survival of mycobacteria. Thus, this recent progress provides a starting point for pursuing this enzyme as a target for the development of novel anti-tubercular drugs. The experiments in this proposal are designed to find inhibitors of Mtb NadD using a combination of structural biology approach and our recently developed virtual screening (VS) methodology. We propose to use our crystal structure of Mtb NadD and previously identified scaffolds active against E. coli and B. anthracis NadD, to apply an iterative ligand- an structure-based VS approach to discover the NadD inhibitors. The VS method will exploit databases with approved drugs that have already been shown to be safe in humans. Upon successful completion of this project we will obtain a number of potent and safe lead compounds that would be further validated in in vivo studies. The strategies developed in the proposed study will be also applicable to other medically relevant targets.

描述（由适用提供）：多药耐药性和广泛的抗药性菌株结核病（MTB）的出现，结核病（TB）的致命剂（TB）代表了对TB控制的主要威胁。迫切需要开发针对以前意外细胞过程的新的，更有效的抗结核药物。该提案的目的是找到一类新型的抗菌化合物活跃发表的MTB。烟酰胺单核苷酸腺苷转移酶（NADD）是NAD生物合成的必不可少的酶，代表了针对细菌病原体的药物发育的高度有希望的靶标。近年来，针对大肠杆菌，枯草芽孢杆菌和炭疽芽孢杆菌开发并验证了许多NADD抑制剂。已发布的数据表明，纳德（Tha Nadd）是分枝杆菌的生长和存活所必需的。这是最近的进步为追求这种酶作为开发新型抗结核药物的目标的起点。该提案中的实验旨在使用结构生物学方法和我们最近开发的虚拟筛选（VS）方法的组合找到MTB NADD的抑制剂。我们建议使用MTB NADD的晶体结构，并以前鉴定出对大肠杆菌和炭疽芽孢杆菌NADD活跃的支架，以采用迭代配体 - 基于结构的VS方法来发现NADD抑制剂。 VS方法将使用已证明在人类安全的批准药物来利用数据库。成功完成该项目后，我们将获得许多潜在和安全的铅化合物，这些化合物将在体内研究中得到进一步验证。拟议研究中制定的策略也将适用于其他与医学相关的目标。